Ionis Pharmaceuticals, Inc. (LON:0JDI)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 9.49B +168.2% |
| Revenue (ttm) | 801.37M +47.5% |
| Net Income | -247.62M |
| EPS | -1.53 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59 |
| Average Volume | 12,085 |
| Open | 75.48 |
| Previous Close | 76.51 |
| Day's Range | 74.83 - 77.00 |
| 52-Week Range | 32.44 - 86.72 |
| Beta | 0.38 |
| RSI | 56.17 |
| Earnings Date | Jul 29, 2026 |
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ionis Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Strong commercial growth is driven by INGREZZA, CRENESSITY, and VYKAT XR, with expanding rare endocrine and psychiatric franchises. The pipeline is robust, with multiple late-stage readouts expected from 2027, and recent acquisitions are immediately accretive. Continued investment in R&D and durable revenue streams position the company for long-term growth.
Ionis to host 2026 virtual Annual Meeting of Stockholders
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corpora...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America ...
Ionis Pharmaceuticals price target raised to $111 from $104 at Oppenheimer
Oppenheimer raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $111 from $104 and keeps an Outperform rating on the shares. The firm notes the stock traded higher following…
Ionis Pharmaceuticals price target raised to $86 from $83 at Stifel
Stifel raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $86 from $83 and keeps a Hold rating on the shares.
Ionis Pharmaceuticals price target raised to $100 from $95 at RBC Capital
RBC Capital raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $95 and keeps an Outperform rating on the shares. The firm cites the company’s better-than-expected Q1…
Ionis Pharmaceuticals price target raised to $125 from $120 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $125 from $120 and keeps a Buy rating on the shares. The firm says management commentary strengthens its…
Ionis Pharmaceuticals price target raised to $115 from $106 at Barclays
Barclays analyst Eliana Merle raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $115 from $106 and keeps an Overweight rating on the shares.
Ionis Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 87% revenue growth, driven by strong TRYNGOLZA and DAWNZERA launches and milestone payments. Guidance for 2026 was raised, with robust commercial and R&D revenue expected, and two major independent launches on track.
Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)
Reports Q1 revenue $246M, consensus $196.01M. “Ionis’ strong performance in the first quarter of 2026 underscores the strength of our commercial and R&D engines. Our independent launches are increasin...
Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M
Consensus $811.3M. “Ionis entered 2026 with strong momentum. We continued this momentum with the first quarter financial results reflecting increased commercial revenue from our independent launches a...
Ionis reports first quarter 2026 financial results and highlights progress on key programs
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the first quarter ended March 31, 2026. “Ion...
Ionis partner GSK announces bepirovirsen NDA accepted for priority review
Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced the FDA has accepted for priority review the new drug application, or NDA, for bepirovirsen, an investigational antisense oligonucleotide, or A...
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Appl...
Ionis Pharmaceuticals price target lowered to $108 from $110 at TD Cowen
TD Cowen lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $108 from $110 and keeps a Buy rating on the shares. The firm updated its model while trimming…
Ionis Pharmaceuticals price target raised to $130 from $95 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $130 from $95 and keeps an Overweight rating on the shares. The firm believes the market opportunity for…
Ionis announces additional results from zilganersen study in AxD
Ionis Pharmaceuticals (IONS) announced additional results from the pivotal study of zilganersen in children and adults living with Alexander disease, a rare, progressive and often fatal neurological c...
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexa...
Ionis Pharmaceuticals initiated with a Buy at Canaccord
Canaccord last night initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $110 price target The firm says the company is executing “very well” in its transition to…
Ionis Pharmaceuticals initiated with a Buy at Canaccord
Canaccord initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $110 price target
Ionis to hold first quarter 2026 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first qua...
Ionis Pharmaceuticals resumed with an Outperform at Raymond James
Raymond James analyst Tiago Fauth resumed coverage of Ionis Pharmaceuticals (IONS) with an Outperform rating and $104 price target The firm sees further upside in the shares given the company’s…
Ionis Pharmaceuticals price target raised to $111 from $100 at BofA
BofA raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $111 from $100 and keeps a Buy rating on the shares. The firm adjusted several targets in conjunction with…
Ionis Pharmaceuticals management to meet with Oppenheimer
Meeting to be held on April 7 hosted by Oppenheimer.
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patien...